trial · primary record
Rilvegostomig
Non-small Cell Lung Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1160 |
| Primary completion | 2030-07-01 |
| Primary endpoint | Overall survival (OS) |
| Registry ID | NCT06692738 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:22.468Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06692738
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Rilvegostomig · compound